31.71
+1.31%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Zhejiang Wecome Pharmaceutical Co
Its shares trade on Shenzhen under the ticker 300878.SZ. It has been listed since 24 August 2020. In the fiscal year to 31 December 2025, it reported revenue of CN¥225.3m and a net loss of CN¥227.3m. At that date it held total assets of CN¥1.25bn and shareholders' equity of CN¥910.4m.
Zhejiang Wecome Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of modern Chinese and western medicines. The company is headquartered in Lishui, Zhejiang. The company went IPO on 2020-08-24. The firm's main products include Yinhuang dripping pills, motherwort soft capsules, motherwort dispersible tablets, Guci capsules, Fengliao Changweikang dispersible tablets, ginseng Jianpi tablets and other Chinese patent medicines, as well as western medicines such as roxithromycin soft capsules. Its production dosage forms cover hard capsules, tablets, granules, soft capsules, and pills. The firm mainly conducts its businesses in the China market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 24 Aug 2020
- Employees
- 1,082
- Website
- zjwk.com ↗
Leadership
Pay as last reported
- Mr. Yang LiuChairman of the Board, General Manager, since 2024
- Ms. Jing WangChief Financial OfficerCN¥97,400
- Ms. Xiaoxia KongDeputy General Manager, Director, since 2021CN¥799,400
- Mr. Jianming WuDeputy General Manager, Director, since 2021CN¥299,200
- Mr. Dexiong DaiDeputy General ManagerCN¥250,500
- Mr. Jingwei DingDeputy General ManagerCN¥162,200
- Ms. Dong LiuDeputy General Manager
- Mr. Zhangqi ZhangDeputy General Manager
- Ms. Ting ZhuSecretary of the Board, Director, since 2021CN¥99,400
- Ms. Lan HaoIndependent DirectorCN¥31,200
- Mr. Jiangfeng LiuIndependent DirectorCN¥31,200
- Ms. Jinxia WangIndependent DirectorCN¥31,200
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Zhejiang Wecome Pharmaceutical's Yinhuang dripping pills are a key product in the Chinese patent medicine segment.
- The company's 1,082 employees support comprehensive R&D and production capabilities in the Health Care sector.
- Lishui, Zhejiang serves as a strategic base for pharmaceutical production and distribution in China.
Weaknesses
- The company's focus on Chinese patent medicines limits its presence in the Western pharmaceutical market.
- Limited international market presence restricts growth beyond China's domestic market.
- Roxithromycin soft capsules represent a small portion of the company's overall product portfolio.
Opportunities
- Expanding into the Chinese market for ginseng Jianpi tablets could increase sales volume significantly.
- Growing demand for motherwort soft capsules in the Health Care sector presents new opportunities.
- Increasing production of Fengliao Changweikang dispersible tablets may capture more market share.
Threats
- Competition from other Chinese pharmaceutical companies in the Lishui region poses a threat.
- Regulatory changes in China's Health Care sector could impact product approvals.
- Overreliance on Chinese patent medicines may face challenges from Western medicine trends.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.